Thomas Reiner, Ph.D., was appointed Head, Radioligand Therapy (RLT) Drug Discovery for Advanced Accelerator Applications (AAA), a Novartis Company, in July 2021. He serves as Executive Director, Radioligand Therapy Lead, at the Novartis Institutes for BioMedical Research (NIBR) and is also a member of the Oncology Leadership Team at Novartis. Prior to joining AAA, Thomas served as an Assistant/Associate Member and Laboratory Head at Memorial Sloan Kettering Cancer Center from 2012 to 2021. During this same period, he also held affiliations as an Assistant/Associate Professor at Gerstner Sloan Kettering Graduate School of Biomedical Sciences and as Associate Professor at Weill Cornell Medical College. He was also a Member of the Sloan Kettering Institute Chemical Biology Program from 2018 to 2021. From 2011 to 2012, Thomas served as an Instructor at Harvard Medical School/Massachusetts General Hospital, and previously as a Postdoctoral Fellow at the Center for Systems Biology at Massachusetts General Hospital from 2009 to 2011. During his academic career, Thomas focused his research on small molecule-, peptide- and nanoparticle-based probes for imaging and radiotherapy, and on the design of companion tools for quantifying target engagement and predicting drug susceptibility. Thomas received his Ph.D. from the Technical University of Munich, Germany, where he trained as a synthetic chemist.